Five Lessons Worth Keeping | Vitality Life Map

ApoE4 and menopause: what your genotype means for brain health

Vitality Life Map
August 03, 2026•11 min read

ApoE4, menopause, and the window your brain is counting on

There's a particular kind of scary that only shows up in your late 40s or 50s. Not the dramatic kind. The quiet kind: you walk into a room and forget why. You take an exit you've taken a thousand times and blank on it for a second. You wonder, just for a moment, whether this is "just menopause" or something you should be worried about.

Dr. Ashanthi Gajaweera, a board-certified neurologist who runs a dementia-prevention practice, has described her own version of that moment: getting turned around driving to her daughter's violin concert, on a route she knew by heart. She's known among friends for having an almost unshakeable sense of direction. That single moment sent her looking for an answer, and it led her somewhere most neurologists never go: into the research on perimenopause and the brain.

That question is worth sitting with, because it turns out your genes and your hormones are having a conversation this decade whether you're part of it or not. One gene in particular is worth knowing your version of, whether or not it turns out to be the one you carry.

The gene everyone half-remembers, and almost no one explains

You may have heard of ApoE4 as "the Alzheimer's gene." That's not quite right, and it undersells what's actually useful about knowing your genotype.

Apolipoprotein E, or ApoE, is better thought of as the moving company for fat and cholesterol in your bloodstream and brain. Its job is to package up cholesterol, pick it up from where it's not needed, and deliver it to the cells that are asking for it, including brain cells, which rely on a steady, well-managed supply. Every one of us runs one of three "editions" of this moving company, called E2, E3, and E4, and we each inherit one copy from each parent, which means six possible combinations.

E3/E3 is the standard-issue version and the most common, showing up in roughly 6 out of 10 people. Somewhere around 1 in 4 or 5 people carry at least one copy of E4, usually paired with an E3 (written E3/E4). A smaller group, roughly 2 to 3 people out of 100, carry two copies (E4/E4). Carrying an E4 copy doesn't mean a diagnosis is coming. It means your particular moving company runs a little differently: it tends to be less efficient at hauling away extra fat and cholesterol, and it changes the odds around brain resilience later in life. Odds, not verdicts.

For what it's worth, mainstream genetics guidance doesn't currently recommend testing everyone's ApoE status purely to predict dementia risk, because on its own the result isn't precise enough to act on. Where it becomes genuinely useful is when you pair it with the two things this article is really about: how your body handles this decade of hormone change, and how your body handles the food on your plate.

Why your 40s and 50s change the math

Estrogen does more than regulate your cycle. It also acts like the reliable power source your brain has been running on for decades, nudging brain cells to burn glucose efficiently for energy. Neuroscientist Dr. Lisa Mosconi, who directs the Women's Brain Initiative at Weill Cornell Medicine, has described this shift in imaging studies: as estrogen declines through perimenopause, the brain's glucose use and connectivity change too, and for most women those changes are temporary as the brain adapts to running on a different fuel mix.

For most women, that adaptation happens quietly in the background. But research increasingly suggests that for women carrying an E4 copy, the menopause transition asks more of the brain right at the moment it has less hormonal support to draw on. A large NIH-funded analysis pooling 27 studies found that women carrying one copy of E4 between ages 65 and 75 faced meaningfully higher odds of Alzheimer's than men with the same genotype at the same age, a gap that mostly closed at older ages. Newer research has gone further, linking the E4 variant to earlier menopause itself, and finding that women who carry E4 and experience early menopause show the highest risk of the group. Dr. Gajaweera puts the bigger picture plainly in her own writing: women are roughly twice as likely as men to develop dementia in their lifetime, and for women who carry E4, that risk tends to arrive earlier and move faster.

None of this is meant to alarm you. It's meant to explain why the years around perimenopause and menopause function less like an ordinary birthday and more like a genuine fork in the road, one where the decisions you make (and the information you have) carry weight that shows up decades later.

Meet the doctor who treats both sides of this conversation

Here's the frustrating part: most neurologists don't touch hormones, and most menopause specialists don't focus on dementia prevention. Women end up bouncing between two experts who never talk to each other, trying to piece together an answer neither one is fully equipped to give.

Dr. Gajaweera is one of a small number of neurologists in the country who is also a Menopause Society Certified Practitioner. With 25 years in practice and a clinic built specifically around dementia prevention, she treats the hormone conversation and the brain conversation as one conversation, not two referrals. It's the equivalent of finally getting your electrician and your architect in the same room instead of collecting two separate opinions about why the lights keep flickering.

Hormones and ApoE4: the honest, complicated truth

This is exactly where Dr. Gajaweera's approach is most useful, because she doesn't pretend the science is simpler than it is.

For years, hormone replacement therapy carried a cloud of fear left over from early-2000s studies that, on closer reading, overstated the risks, particularly around breast cancer. More recent imaging research in cognitively healthy postmenopausal women has found that those using hormone therapy tend to show fewer of the brain changes associated with Alzheimer's risk: more brain volume, less amyloid buildup, healthier glucose metabolism. One large European cohort study found that E4 carriers using hormone therapy actually showed better memory performance and larger brain volume in specific regions compared to E4 carriers who weren't using it, with earlier initiation appearing to matter.

But the honest picture isn't a straight line. A more recent observational study found the opposite pattern in a different sample: E4-carrying women using hormone therapy showed worse levels of certain Alzheimer's-related markers in spinal fluid compared to non-users. Two well-designed studies, two different results, in the same genetic subgroup.

That's not a reason to throw up your hands. It's the reason a decision like this isn't a light switch, on for everyone or off for everyone. It's more like a thermostat: the right setting depends on your starting temperature, meaning your genotype, your timing, your personal and family history, and your other risk factors, worked out with a clinician who actually understands both sides of the equation.

What eight years and two very different plates taught me about my own genotype

Here's where this stops being theoretical for me.

Back in 2017, I was eating a mostly pescatarian way, light on meat, heavier on fish and plants. My lipid panel from that year looked like this:

  • Total cholesterol: 158

  • LDL: 87

  • HDL: 53

  • Triglycerides: 89

This year, in 2025, I ran a very different experiment, though I didn't fully realize it was one at the time. Over roughly two months, my eating went in cycles: six weeks of about 90 percent meat with some fish, then a week of leaning back into greens and root vegetables, then another week of about 90 percent meat, then a week of greens and root vegetables with seafood. Even with those lighter weeks mixed in, the overall stretch was predominantly meat. Here's what my labs showed after that:

  • Total cholesterol: 255

  • LDL: 155

  • HDL: 74 (higher than 2017, which on its own reads as good news)

  • Triglycerides: 140

The basic panel alone was enough to get my attention, but the deeper part of the 2025 draw is what really explained things. That panel didn't stop at the standard four numbers. It also measured the actual particles doing the work of carrying that cholesterol around: LDL particle number came back at 2,094 (too high), small LDL particles at 658 (way too high), medium LDL particles at 585 (too high), HDL particles at 7,350 (good), and my LDL pattern came back as "B," meaning more of my LDL is running small and dense rather than large and buoyant. My LDL size score came in at 215, when the preferred range is above 222.

Here's why that detail matters more than the basic panel alone. Small, dense LDL particles are generally considered more prone to working their way into artery walls than the larger, fluffier kind, so two people can share an identical LDL number on paper and be carrying very different levels of risk depending on the size and number of particles behind it. My HDL number went up between 2017 and 2025, which taken by itself looks favorable. Set against the full particle picture, one improved number didn't offset the rest of the shift. My own labs put it plainly: my best numbers came during the years I ate a more pescatarian, plant-forward way with low animal fat, and what they're telling me now is that returning to that style of eating is the direction that serves me.

This lines up with what the research above would predict for someone carrying an E4 copy. Several controlled studies have found that people with an E4 allele tend to show a more pronounced rise in LDL cholesterol when saturated fat intake goes up, compared to people with the standard E3/E3 genotype, likely because the E4 version of that moving company is slower to clear fat-carrying particles once a lot of them show up in the bloodstream at once. Other well-run studies have found no meaningful difference at all. The honest summary is that the population-level research is mixed, which is precisely why your own numbers, tested before and after a real change, tell you something a study average never can.

I want to be clear about what this is and isn't. This is one woman's lived experience, not a promise of what will happen to you. Genotype is one variable among many, alongside how much your diet actually changed, your baseline health, your movement, your stress, your sleep. But it's exactly the kind of evidence a PhD's standard would ask for: not a guess, a before-and-after, on my own body, that matched what the literature said I should expect.

So what do you actually do with this?

You don't need to fear a burger. You do deserve to stop guessing.

If you don't know your ApoE genotype, it's a simple blood test, and it's worth having in your file even if you never think about dementia risk again, because it also shapes how your body is likely to respond to dietary fat. If you don't carry an E4 copy, that's useful to know, and it means dietary fat is less likely to swing your numbers dramatically. If you do carry one or two copies, it isn't a diagnosis. It's information that makes two conversations worth having sooner rather than later: what a higher-fat way of eating is actually doing to your own labs, and what hormone therapy timing looks like for someone with your specific genetics and history.

A few questions worth bringing to your next appointment:

  • What is my full ApoE genotype, not just whether I carry an E4 copy?

  • Given my genotype and family history, does starting hormone therapy in this window make sense for me, and if so, which form?

  • Should I get a lipid panel before and after any significant change to how I eat?

  • Am I working with someone who understands both my hormones and my brain health, or am I piecing this together myself?

Trusting your own data

You don't need a genetics degree to have this conversation. You need your genotype, a recent lipid panel, and a clinician willing to look at both together. Bring the checklist above to your next appointment, and let your own numbers, not a population average, guide what comes next.

None of that replaces the deeper testing this article is about. Your genotype and a full lipid panel still take an actual blood draw. But if this also has you thinking more broadly about your energy, and where it's going, the Vitality Assessment™ is built for that different starting point. It works from questions, not bloodwork, and it's meant to help you see what's worth looking at next.

Sources and further reading

The information provided is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider regarding your individual health needs.

Back to Blog